Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis

  1. Teja Turk
  2. Nadine Bachmann
  3. Claus Kadelka
  4. Jürg Böni
  5. Sabine Yerly
  6. Vincent Aubert
  7. Thomas Klimkait
  8. Manuel Battegay
  9. Enos Bernasconi
  10. Alexandra Calmy
  11. Matthias Cavassini
  12. Hansjakob Furrer
  13. Matthias Hoffmann
  14. Huldrych F Günthard
  15. Roger D Kouyos  Is a corresponding author
  1. University Hospital Zurich, Switzerland
  2. University of Hospital Zurich, Switzerland
  3. University of Zurich, Switzerland
  4. Geneva University Hospitals, Switzerland
  5. University Hospital Lausanne, Switzerland
  6. University of Basel, Switzerland
  7. University Hospital Basel, Switzerland
  8. Regional Hospital of Lugano, Switzerland
  9. Geneva University Hospital, Switzerland
  10. Lausanne University Hospital, Switzerland
  11. University of Bern, Switzerland
  12. Cantonal Hospital St. Gallen, Switzerland
  13. University Hospital Zürich, Switzerland

Abstract

Assessing the danger of transition of HIV transmission from a concentrated to a generalized epidemic is of major importance for public health. In this study, we develop a phylogeny-based statistical approach to address this question. As a case study, we use this to investigate the trends and determinants of HIV transmission among Swiss heterosexuals. We extract the corresponding transmission clusters from a phylogenetic tree. To capture the incomplete sampling, the delayed introduction of imported infections to Switzerland, and potential factors associated with basic reproductive number R0, we extend the branching process model to infer transmission parameters. Overall, the R0 is estimated to be 0.44 (95%-confidence interval 0.42-0.46) and it is decreasing by 11% per 10 years (4%-17%). Our findings indicate rather diminishing HIV transmission among Swiss heterosexuals far below the epidemic threshold. Generally, our approach allows to assess the danger of self-sustained epidemics from any viral sequence data.

Article and author information

Author details

  1. Teja Turk

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3065-8578
  2. Nadine Bachmann

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7303-9542
  3. Claus Kadelka

    Division of Infectious Diseases and Hospital Epidemiology, University of Hospital Zurich, Zurich, Switzerland
    Competing interests
    No competing interests declared.
  4. Jürg Böni

    Institute of Medical Virology, University of Zurich, Zurich, Switzerland
    Competing interests
    No competing interests declared.
  5. Sabine Yerly

    Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
    Competing interests
    No competing interests declared.
  6. Vincent Aubert

    Divisions of Immunology and Allergy, University Hospital Lausanne, Lausanne, Switzerland
    Competing interests
    No competing interests declared.
  7. Thomas Klimkait

    Department of Biomedicine, University of Basel, Basel, Switzerland
    Competing interests
    No competing interests declared.
  8. Manuel Battegay

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Competing interests
    No competing interests declared.
  9. Enos Bernasconi

    Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland
    Competing interests
    Enos Bernasconi, E.B. has been a consultant for BMS, Gilead, ViiV Healthcare, Pfizer, MSD, and Janssen; has received unrestricted research grants from Gilead, Abbott, Roche, and MSD; and has received travel grants from BMS, Boehringer Ingelheim, Gilead, MSD, and Janssen..
  10. Alexandra Calmy

    Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    Competing interests
    No competing interests declared.
  11. Matthias Cavassini

    Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland
    Competing interests
    No competing interests declared.
  12. Hansjakob Furrer

    Department of Infectious Diseases, University of Bern, Bern, Switzerland
    Competing interests
    Hansjakob Furrer, The institution of H.F. has received unrestricted grant support from ViiV, Gilead, Abbott, Janssen, Roche, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), and Boehringer Ingelheim..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1375-3146
  13. Matthias Hoffmann

    Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
    Competing interests
    No competing interests declared.
  14. Huldrych F Günthard

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Zürich, Switzerland
    Competing interests
    Huldrych F Günthard, H.F.G. has been an adviser and/or consultant for GlaxoSmithKline, Abbott, Gilead, Novartis, Boehringer Ingelheim, Roche, Tibotec, Pfizer, and BMS and has received unrestricted research and educational grants from Roche, Abbott, BMS, Gilead, Astra-Zeneca, GlaxoSmithKline, and MSD (all money to the institution)..
  15. Roger D Kouyos

    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    For correspondence
    roger.kouyos@usz.ch
    Competing interests
    Roger D Kouyos, RDK has received speaker honoraria and travel grants from Gilead Sciences. None if these are in relation with the submitted manuscript..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9220-8348

Funding

Swiss National Science Foundation (33CS30-148522 and 159868)

  • Huldrych F Günthard

Swiss National Science Foundation (PZ00P3-142411)

  • Roger D Kouyos

Yvonne-Jacob Foundation

  • Huldrych F Günthard

University of Zurich's Clinical Research Priority Program's ZPHI

  • Huldrych F Günthard

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Ryosuke Omori

Ethics

Human subjects: The SHCS was approved by the ethics committees of the participating institutions (Kantonale Ethikkommission Bern, Ethikkommission des Kantons St. Gallen, Comite Departemental d'Ethique des Specialites Medicales et de Medicine Communataire et de Premier Recours, Kantonale Ethikkommission Zürich, Repubblica e Cantone Ticino-Comitato Ethico Cantonale, Commission Cantonale d'Étique de la Recherche sur l'Être Humain, Ethikkommission beiderBasel; all approvals are available on http://www.shcs.ch/206-ethic-committee-approval-and-informed-consent), and written informed consent was obtained from all participants.

Version history

  1. Received: May 17, 2017
  2. Accepted: August 28, 2017
  3. Accepted Manuscript published: September 12, 2017 (version 1)
  4. Version of Record published: October 20, 2017 (version 2)

Copyright

© 2017, Turk et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,431
    views
  • 230
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Teja Turk
  2. Nadine Bachmann
  3. Claus Kadelka
  4. Jürg Böni
  5. Sabine Yerly
  6. Vincent Aubert
  7. Thomas Klimkait
  8. Manuel Battegay
  9. Enos Bernasconi
  10. Alexandra Calmy
  11. Matthias Cavassini
  12. Hansjakob Furrer
  13. Matthias Hoffmann
  14. Huldrych F Günthard
  15. Roger D Kouyos
(2017)
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis
eLife 6:e28721.
https://doi.org/10.7554/eLife.28721

Share this article

https://doi.org/10.7554/eLife.28721

Further reading

    1. Epidemiology and Global Health
    Sean V Connelly, Nicholas F Brazeau ... Jeffrey A Bailey
    Research Article

    Background:

    The Zanzibar archipelago of Tanzania has become a low-transmission area for Plasmodium falciparum. Despite being considered an area of pre-elimination for years, achieving elimination has been difficult, likely due to a combination of imported infections from mainland Tanzania and continued local transmission.

    Methods:

    To shed light on these sources of transmission, we applied highly multiplexed genotyping utilizing molecular inversion probes to characterize the genetic relatedness of 282 P. falciparum isolates collected across Zanzibar and in Bagamoyo district on the coastal mainland from 2016 to 2018.

    Results:

    Overall, parasite populations on the coastal mainland and Zanzibar archipelago remain highly related. However, parasite isolates from Zanzibar exhibit population microstructure due to the rapid decay of parasite relatedness over very short distances. This, along with highly related pairs within shehias, suggests ongoing low-level local transmission. We also identified highly related parasites across shehias that reflect human mobility on the main island of Unguja and identified a cluster of highly related parasites, suggestive of an outbreak, in the Micheweni district on Pemba island. Parasites in asymptomatic infections demonstrated higher complexity of infection than those in symptomatic infections, but have similar core genomes.

    Conclusions:

    Our data support importation as a main source of genetic diversity and contribution to the parasite population in Zanzibar, but they also show local outbreak clusters where targeted interventions are essential to block local transmission. These results highlight the need for preventive measures against imported malaria and enhanced control measures in areas that remain receptive to malaria reemergence due to susceptible hosts and competent vectors.

    Funding:

    This research was funded by the National Institutes of Health, grants R01AI121558, R01AI137395, R01AI155730, F30AI143172, and K24AI134990. Funding was also contributed from the Swedish Research Council, Erling-Persson Family Foundation, and the Yang Fund. RV acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 program supported by the European Union. RV also acknowledges funding by Community Jameel.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Patrick E Brown, Sze Hang Fu ... Ab-C Study Collaborators
    Research Article

    Background: Few national-level studies have evaluated the impact of 'hybrid' immunity (vaccination coupled with recovery from infection) from the Omicron variants of SARS-CoV-2.

    Methods: From May 2020 to December 2022, we conducted serial assessments (each of ~4000-9000 adults) examining SARS-CoV-2 antibodies within a mostly representative Canadian cohort drawn from a national online polling platform. Adults, most of whom were vaccinated, reported viral test-confirmed infections and mailed self-collected dried blood spots to a central lab. Samples underwent highly sensitive and specific antibody assays to spike and nucleocapsid protein antigens, the latter triggered only by infection. We estimated cumulative SARS-CoV-2 incidence prior to the Omicron period and during the BA.1/1.1 and BA.2/5 waves. We assessed changes in antibody levels and in age-specific active immunity levels.

    Results: Spike levels were higher in infected than in uninfected adults, regardless of vaccination doses. Among adults vaccinated at least thrice and infected more than six months earlier, spike levels fell notably and continuously for the nine months post-vaccination. By contrast, among adults infected within six months, spike levels declined gradually. Declines were similar by sex, age group, and ethnicity. Recent vaccination attenuated declines in spike levels from older infections. In a convenience sample, spike antibody and cellular responses were correlated. Near the end of 2022, about 35% of adults above age 60 had their last vaccine dose more than six months ago, and about 25% remained uninfected. The cumulative incidence of SARS-CoV-2 infection rose from 13% (95% CI 11-14%) before omicron to 78% (76-80%) by December 2022, equating to 25 million infected adults cumulatively. However, the COVID-19 weekly death rate during the BA.2/5 waves was less than half of that during the BA.1/1.1 wave, implying a protective role for hybrid immunity.

    Conclusions: Strategies to maintain population-level hybrid immunity require up-to-date vaccination coverage, including among those recovering from infection. Population-based, self-collected dried blood spots are a practicable biological surveillance platform.

    Funding: Funding was provided by the COVID-19 Immunity Task Force, Canadian Institutes of Health Research, Pfizer Global Medical Grants, and St. Michael's Hospital Foundation. PJ and ACG are funded by the Canada Research Chairs Program.